Global Penny Stocks With At Least US$900M Market Cap

Global markets have recently experienced mixed performances, with U.S. stock indexes showing varied results amid geopolitical tensions and energy market volatility. Despite these fluctuations, certain investment opportunities continue to capture attention, particularly in the realm of penny stocks. Often representing smaller or newer companies, penny stocks remain a relevant investment area that can offer growth potential when supported by strong financial health and fundamentals.

Let's review some notable picks from our screened stocks.

Shaanxi Beiyuan Chemical Industry Group (SHSE:601568)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Shaanxi Beiyuan Chemical Industry Group Co., Ltd. operates in the chemical industry and has a market capitalization of CN¥13.70 billion.

Operations: Shaanxi Beiyuan Chemical Industry Group Co., Ltd. does not report specific revenue segments.

Market Cap: CN¥13.7B

Shaanxi Beiyuan Chemical Industry Group faces challenges with declining earnings, having dropped by 52.4% per year over the past five years, and recent financials show a net income decrease to CN¥20.48 million from CN¥87.8 million a year ago. Despite this, the company maintains a strong balance sheet with no debt and short-term assets exceeding liabilities significantly. The stock trades at 53.8% below its estimated fair value, which might attract investors seeking undervalued opportunities in the chemical sector. However, low profit margins and an inexperienced board could pose risks to potential growth and stability in this volatile market segment.

• Get an in-depth perspective on Shaanxi Beiyuan Chemical Industry Group's performance by reading our balance sheet health report here.
• Review our historical performance report to gain insights into Shaanxi Beiyuan Chemical Industry Group's track record.

Northeast Pharmaceutical Group (SZSE:000597)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Northeast Pharmaceutical Group Co., Ltd. operates in China, focusing on chemical pharmaceuticals manufacturing, pharmaceutical distribution, pharmaceutical engineering, and biopharmaceuticals, with a market cap of CN¥6.59 billion.

Operations: There are no specific revenue segments reported for Northeast Pharmaceutical Group.

Market Cap: CN¥6.59B

Northeast Pharmaceutical Group's recent performance highlights mixed outcomes for investors in the penny stock space. The company reported a slight increase in sales to CN¥2.01 billion for Q1 2026, yet net income fell to CN¥26.63 million from CN¥36.32 million a year prior, indicating pressure on profit margins which have declined to 3.5%. Despite negative earnings growth over the past year, its balance sheet remains robust with short-term assets exceeding both short and long-term liabilities significantly, and cash surpassing total debt levels. However, an unstable dividend track record and low return on equity may concern some investors seeking consistent returns.

• Click here and access our complete financial health analysis report to understand the dynamics of Northeast Pharmaceutical Group.
• Learn about Northeast Pharmaceutical Group's historical performance here.

Huapont Life SciencesLtd (SZSE:002004)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Huapont Life Sciences Co., Ltd. operates in diverse sectors including medicine, medical care, agrochemicals, new materials, and tourism both in China and internationally, with a market cap of CN¥8.27 billion.

Operations: No specific revenue segments are reported for Huapont Life Sciences Co., Ltd.

Market Cap: CN¥8.27B

Huapont Life Sciences Co., Ltd. presents a complex picture for investors in the penny stock domain. The company has achieved profitability recently, with net income reaching CN¥713.19 million for 2025, reversing a loss from the previous year. Despite earnings declining by an average of 30.4% annually over five years, its financial health is supported by short-term assets exceeding liabilities and a reduced debt-to-equity ratio of 46.1%. However, low return on equity at 5.1% and an unsustainable dividend yield of 11.68% may pose concerns for those seeking stable returns in this volatile segment.

• Take a closer look at Huapont Life SciencesLtd's potential here in our financial health report.
• Examine Huapont Life SciencesLtd's past performance report to understand how it has performed in prior years.

Next Steps

• Access the full spectrum of 3,607 Global Penny Stocks by clicking on this link.
• Ready For A Different Approach? Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com